Groth H, Vetter H, Knüsel J, Boerlin H J, Walger P, Baumgart P, Wehling M, Siegenthaler W, Vetter W
Schweiz Med Wochenschr. 1983 Dec 10;113(49):1841-5.
The antihypertensive efficacy and side effects of a transdermal therapeutic system containing 2.5 mg clonidine (clonidine-TTS) was investigated in 21 patients with essential hypertension over a period of 10 weeks. The system was designed to release 0.1 mg clonidine/24 h. Mean systolic and diastolic blood pressure fell from 160 +/- 17/106 +/- 7 mm Hg to 139 +/- 16/91 +/- 8 mm Hg after 4 weeks and to 135 +/- 14/89 +/- 8 mm Hg after 10 weeks (p less than 0.001). Sufficient blood pressure control was achieved by one clonidine-TTS weekly in 24% and by 2 clonidine-TTS in 33% of the patients. 43% of all cases required additional oral therapy with 50 mg hydrochlorothiazide/day. However, antihypertensive action was accompanied by a high incidence of local skin reactions. These skin reactions with erythema, itching and red papules occurred in 6 of the 21 patients (29%) after treatment with TTS for at least 4 weeks. Patch testing with the various components of clonidine-TTS in 4 patients identified clonidine-allergy of delayed type in 3 cases. Typical clonidine side effects such as fatigue, dry mouth, constipation and sexual disturbances were moderate. It is concluded that clonidine-TTS has a good and continuous antihypertensive action. However, the high incidence of skin reactions limits its use in the treatment of essential hypertension.
对21例原发性高血压患者进行了为期10周的研究，以调查含2.5毫克可乐定的透皮治疗系统（可乐定透皮贴剂）的降压疗效及副作用。该系统设计为每24小时释放0.1毫克可乐定。4周后，平均收缩压和舒张压从160±17/106±7毫米汞柱降至139±16/91±8毫米汞柱，10周后降至135±14/89±8毫米汞柱（p<0.001）。24%的患者每周使用一片可乐定透皮贴剂、33%的患者每周使用两片可乐定透皮贴剂即可实现充分的血压控制。所有病例中有43%需要额外口服50毫克氢氯噻嗪/天进行治疗。然而，降压作用伴随着较高的局部皮肤反应发生率。21例患者中有6例（29%）在使用透皮贴剂治疗至少4周后出现了伴有红斑、瘙痒和红色丘疹的皮肤反应。对4例患者用可乐定透皮贴剂的各种成分进行斑贴试验，发现3例为迟发型可乐定过敏。典型的可乐定副作用如疲劳、口干、便秘和性功能障碍较为轻微。结论是可乐定透皮贴剂具有良好且持续的降压作用。然而，皮肤反应的高发生率限制了其在原发性高血压治疗中的应用。
